The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Figures for:
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor–Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase 3 Study (PALOMA-3)
Sunil Verma et al.



Figure S1. (A) Time to onset of hematologic toxicity in the palbociclib plus fulvestrant arm only and (B) duration of each episode by grade analysis based on laboratory data. Includes patients with postbaseline CTCAEs grade >0 and greater than baseline CTCAE grade. Percentages are based on number of episodes in each subgroup. For multiple time to recovery periods within a patient, an average was calculated prior to summarizing among patients.
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events.

The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Figures for:
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor–Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase 3 Study (PALOMA-3)
Sunil Verma et al.



Figure S2. Mean relative dose intensities for treatment arms by cycle number. Dose intensity was defined as the actual dose intensity divided by the intended dose intensity multiplied by 100%.

The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Figures for:
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor–Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase 3 Study (PALOMA-3)
Sunil Verma et al.



Patients at risk																
At least 1 dose reduction	114	112	101	98	92	91	76	75	42	40	10	8	3	3	1	0
0 dose reduction	231	221	180	175	155	153	126	122	49	45	22	15	4	4	0	

Figure S3. Kaplan-Meier plot of patients in the palbociclib plus fulvestrant arm who had at least 1 dose reduction because of adverse events (*n* = 114) vs no dose reduction (*n* = 231).
Abbreviation: NE, not estimable.